Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
Joseph ReedTony DongElke EatonJanice FriswoldJodie PorgesSadeer G Al-KindiSanjay RajagopalanIan J NeelandPublished in: Diabetes, obesity & metabolism (2024)
Dexcom G6 CGM was associated with improved glycaemic control and cardiometabolic risk in patients with T2DM who were not on insulin. CGM can be a safe and effective tool to improve diabetes management in patients at high risk for adverse cardiovascular outcomes.
Keyphrases
- type diabetes
- glycemic control
- clinical trial
- end stage renal disease
- ejection fraction
- cardiovascular disease
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- insulin resistance
- stem cells
- randomized controlled trial
- open label
- emergency department
- patient reported outcomes
- adipose tissue
- phase ii
- double blind
- weight loss
- patient reported
- cell therapy